{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T03:40:13Z","timestamp":1792554013846,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,5,20]],"date-time":"2019-05-20T00:00:00Z","timestamp":1558310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,5,20]],"date-time":"2019-05-20T00:00:00Z","timestamp":1558310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1007\/s41669-019-0141-4","type":"journal-article","created":{"date-parts":[[2019,5,21]],"date-time":"2019-05-21T12:01:59Z","timestamp":1558440119000},"page":"5-12","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Systematic Review of Economic Evaluations in Primary Open-Angle Glaucoma: Decision Analytic Modeling Insights"],"prefix":"10.1007","volume":"4","author":[{"given":"Jose","family":"Bartelt-Hofer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilia","family":"Ben-Debba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Flessa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,20]]},"reference":[{"key":"141_CR1","unstructured":"Deutsche Ophthalologische Gesellschaft, \u201cStellungnahme zur Glaukomfr\u00fcherkennung,\u201d 2015. [Online]. \n                  https:\/\/www.dog.org\/wp-content\/uploads\/2015\/11\/SN-Glaukom-August-2015.pdf\n                  \n                . Accessed 28 Sep 2018."},{"key":"141_CR2","first-page":"189","volume":"10","author":"G Richter","year":"2016","unstructured":"Richter G, Coleman A. Minimally invasive glaucoma surgery: current status and future prospects. Clin Ophthalmol. 2016;10:189\u2013206.","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"141_CR3","first-page":"41","volume":"123","author":"American Academy of Ophthalmology","year":"2015","unstructured":"American Academy of Ophthalmology. Primary open-angle glaucoma preferred practice pattern guidelines. Ophthalmology. 2015;123(1):41\u2013111.","journal-title":"Ophthalmology"},{"issue":"5","key":"141_CR4","first-page":"18","volume":"82","author":"N Schellak","year":"2015","unstructured":"Schellak N, Schellak G, Bezuidenhout S. Glaucoma: a brief review. South Afr Pharm J. 2015;82(5):18\u201322.","journal-title":"South Afr Pharm J"},{"issue":"52","key":"141_CR5","first-page":"1","volume":"95","author":"R Paletta Guedes","year":"2016","unstructured":"Paletta Guedes R, Paletta Guedes V, de Mello Gomes CE, Chaoubah A. Maximizing cost-effectiveness by adjusting treatment strategy according to glaucoma severity. Medicine. 2016;95(52):1\u20138.","journal-title":"Medicine"},{"issue":"5","key":"141_CR6","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","volume":"8","author":"D Moher","year":"2010","unstructured":"Moher D, Liberati A, Tezlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8(5):336\u201341.","journal-title":"Int J Surg"},{"issue":"4","key":"141_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bjophthalmol-2016-EGSguideline.001","volume":"101","author":"European Glaucoma Society","year":"2017","unstructured":"European Glaucoma Society. Terminology and guidelines for glaucoma. Br J Ophthalmol. 2017;101(4):1\u201372.","journal-title":"Br J Ophthalmol"},{"key":"141_CR8","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.puhe.2017.11.004","volume":"155","author":"D John","year":"2018","unstructured":"John D, Parikh R. Cost-effectiveness of community screening for glaucoma in rural India: a decision analytical model. Public Health. 2018;155:142\u201351.","journal-title":"Public Health"},{"key":"141_CR9","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.puhe.2017.02.016","volume":"148","author":"D John","year":"2017","unstructured":"John D, Parikh R. Cost-effectiveness and cost utility of community screening for glaucoma in urban India. Public Health. 2017;148:37\u201348.","journal-title":"Public Health"},{"issue":"1","key":"141_CR10","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1097\/OPX.0b013e3181fc30f3","volume":"88","author":"JS Wittenborn","year":"2011","unstructured":"Wittenborn JS, Rein DB. The cost-effectiveness of glaucoma interventions in Barbados and Ghana. Optom Vis Sci. 2011;88(1):155\u201363.","journal-title":"Optom Vis Sci"},{"key":"141_CR11","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1111\/j.1755-3768.2007.00947.x","volume":"85","author":"H Vaahtoranta-Lehtonen","year":"2007","unstructured":"Vaahtoranta-Lehtonen H, Tuulonen A, Aronen P, Sintonen H, Suoranta L, Kovanen N, Linna M, L\u00e4\u00e4r\u00e4 E, Malmivaara A. Cost effectiveness and cost utility of an organized screening programme for glaucoma. Acta Ophthalmol Scand. 2007;85:508\u201318.","journal-title":"Acta Ophthalmol Scand"},{"issue":"2","key":"141_CR12","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1017\/S0266462308080288","volume":"24","author":"RA Hernandez","year":"2008","unstructured":"Hernandez RA, Burr JM, Vale LD. Economic evaluation of screening for open-angle glaucoma. Int J Technol Assess Health Care. 2008;24(2):203\u20132011.","journal-title":"Int J Technol Assess Health Care"},{"issue":"611","key":"141_CR13","first-page":"2","volume":"16","author":"T Boodhna","year":"2016","unstructured":"Boodhna T, Crabb DP. More frequent, more costly? Health economic modelling aspects of monitoring glaucoma patients in England. Health Serv Res. 2016;16(611):2\u201313.","journal-title":"Health Serv Res"},{"issue":"1","key":"141_CR14","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/j.1755-3768.2011.02318.x","volume":"90","author":"A van Gestel","year":"2012","unstructured":"van Gestel A, Webers CA, Severens JL, Beckers HJ, Jansonius N, Hendrikse F, Schouten J. The long-term outcomes of four alternative treatment strategies for primary open-angle glaucoma. Acta Ophthalmol. 2012;90(1):20\u201331.","journal-title":"Acta Ophthalmol"},{"issue":"7","key":"141_CR15","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1097\/IJG.0b013e31821dac2a","volume":"21","author":"M Orme","year":"2012","unstructured":"Orme M, Collins S, Loftus J. Long-term medical management of primary open-angle glaucoma and ocular hypertension in the UK: optimizing cost-effectiveness and clinic resources by minimizing therapy switches. J Glaucoma. 2012;21(7):433\u201349.","journal-title":"J Glaucoma"},{"issue":"1","key":"141_CR16","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/sj.eye.6702964","volume":"23","author":"W Stewart","year":"2009","unstructured":"Stewart W, Stewart J, Mychaskiw M. Cost-effectiveness of latanoprost and timolol maleate for the treatment of glaucoma in Scandinavia and the United Kingdom, using a decision-analytic health economic model. Eye. 2009;23(1):132\u201340.","journal-title":"Eye"},{"issue":"4","key":"141_CR17","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1001\/archophthalmol.2011.2727","volume":"130","author":"J Stein","year":"2012","unstructured":"Stein J, Kim D, Peck W, Giannetti S, Hutton D. Cost effectiveness of medications compared with laser trabeculoplasty in patients with newly-diagnosed open-angle glaucoma. Arch Ophthalmol. 2012;130(4):497\u2013505.","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"141_CR18","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1590\/S0004-27492012000100002","volume":"75","author":"RA Paletta Guedes","year":"2012","unstructured":"Paletta Guedes RA, Paletta Guedes VM, Chaoubah A. Cost-effectiveness comparison between non-penetrating deep sclerectomy and maximum-tolerated medical therapy for glaucoma within the Brazilian National Health System. Arq Bras Oftalmol. 2012;75(1):11\u20135.","journal-title":"Arq Bras Oftalmol"},{"issue":"5","key":"141_CR19","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1001\/jamaophthalmol.2015.44","volume":"133","author":"RI Kaplan","year":"2015","unstructured":"Kaplan RI, de Morales G, Cioffi GA, Al-Aswad LA, Blumberg D. Comparative Cost-effectiveness of the Baerveldt Implant, Trabeculectomy With Mitomycin, and Medical Treatment. JAMA Ophthalmol. 2015;133(5):560\u20137.","journal-title":"JAMA Ophthalmol"},{"issue":"2","key":"141_CR20","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1080\/03007995.2018.1506022","volume":"35","author":"J Ord\u00f3\u00f1ez","year":"2019","unstructured":"Ord\u00f3\u00f1ez J, Ord\u00f3\u00f1ez A, Osorio U. Cost-effectiveness analysis of iStent trabecular micro-bypass stent for patients with open-angle glaucoma in Colombia. Curr Med Res Opin. 2019;35(2):329\u201340.","journal-title":"Curr Med Res Opin"},{"issue":"8","key":"141_CR21","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1097\/IJG.0b013e31821dac66","volume":"21","author":"M Ng","year":"2012","unstructured":"Ng M, Sample P, Pascual J, Zangwill L, Girkin C, Liebmann J, Weinreb R, Racette L. Comparison of visual field severity classification systems for glaucoma. J Glaucoma. 2012;21(8):551\u201361.","journal-title":"J Glaucoma"},{"issue":"1","key":"141_CR22","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ajo.2005.07.044","volume":"141","author":"RP Mills","year":"2006","unstructured":"Mills RP, Budenz D, Lee PP, Noecker RJ, Walt JG, Siegartel LR, Evans SJ, Doyle JJ. Categorizing the stage of glaucoma from pre-diagnosis to end-stage disease. Am J Opthalmol. 2006;141(1):24\u201330.","journal-title":"Am J Opthalmol"},{"key":"141_CR23","unstructured":"CADTH. Pharmacoeconomic review report for monoprost. May 2018. [Online]. \n                  https:\/\/www.cadth.ca\/sites\/default\/files\/cdr\/pharmacoeconomic\/SR0541_Monoprost_PE_Report.pdf\n                  \n                . Accessed 07 Feb 2019."},{"issue":"1","key":"141_CR24","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.ophtha.2008.12.056","volume":"116","author":"DB Rein","year":"2009","unstructured":"Rein DB, Wittenborn JS, Lee PP, Wirth KE, Sorensen SW, Hoerger TJ, Saaddine JB. The cost-effectiveness of routine office-based identification and subsequent medical treatment of primary open-angle glaucoma in the United States. Ophthalmology. 2009;116(1):823\u201332.","journal-title":"Ophthalmology"},{"issue":"1","key":"141_CR25","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/sj.eye.6702637","volume":"22","author":"A Peeters","year":"2008","unstructured":"Peeters A, Schouten J, Webers C, Prins M, Hendrikse F, Severens J. Cost-effectiveness of early detection and treatment of ocular hypertension and primary open-angle glaucoma by the ophthalmologist. Eye. 2008;22(1):354\u201362.","journal-title":"Eye"},{"issue":"3","key":"141_CR26","doi-asserted-by":"publisher","first-page":"183","DOI":"10.2165\/00044011-200828030-00005","volume":"28","author":"S Payet","year":"2008","unstructured":"Payet S, Denis P, Berdeaux G, Launois R. Assessment of the cost effectiveness of travoprost versus latanoprost as single agents for treatment of glaucoma in France. Clin Drug Invest. 2008;28(3):183\u201398.","journal-title":"Clin Drug Invest"},{"key":"141_CR27","doi-asserted-by":"publisher","first-page":"S30","DOI":"10.1177\/112067210301304S04","volume":"13","author":"L Bernard","year":"2003","unstructured":"Bernard L, Althin R, Dhawan R, Grima D, Lam A, Aball\u00e9a S. Clinical and economic impacts of latanoprost 0.005% in first-line treatment of open-angle glaucoma and ocular hypertension in France. Eur J Ophthalmol. 2003;13:S30\u201343.","journal-title":"Eur J Ophthalmol"},{"issue":"S229","key":"141_CR28","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/j.1600-0420.1999.tb01154.x","volume":"77","author":"C Eandi","year":"1999","unstructured":"Eandi C, Brogliatti B, Micieli M, Grignolo F. Cost -effective analysis by Markov Chains of open-angle glaucoma therapy. Preliminary results. Acta Ophthalmol. 1999;77(S229):56\u20137.","journal-title":"Acta Ophthalmol"},{"issue":"6","key":"141_CR29","first-page":"414","volume":"32","author":"A Rochi","year":"1997","unstructured":"Rochi A, Tingey D. Economic evaluation of dorzolamide vs. pilocarpine for primary open-angle glaucoma. Can J Ophthalmol. 1997;32(6):414\u20138.","journal-title":"Can J Ophthalmol"},{"issue":"3","key":"141_CR30","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/0039-6257(83)90098-X","volume":"28","author":"L Gottlieb","year":"1983","unstructured":"Gottlieb L, Schwartz B, Pauker S. Glaucoma screening. A cost-effectiveness analysis. Surv Opthalmol. 1983;28(3):206\u201326.","journal-title":"Surv Opthalmol"}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-019-0141-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s41669-019-0141-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-019-0141-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T07:29:23Z","timestamp":1597303763000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s41669-019-0141-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,20]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["141"],"URL":"https:\/\/doi.org\/10.1007\/s41669-019-0141-4","relation":{},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"value":"2509-4262","type":"print"},{"value":"2509-4254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,20]]},"assertion":[{"value":"20 May 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No sources of funding were used to conduct this review or prepare this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"J. Bartelt-Hofer, L. Ben-Debba, and S. Flessa have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}